Advances in Hematology / 2012 / Article / Tab 1

Review Article

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

Table 1

Evidence of aberrant activation of mTORC1, PI3K/Akt, and Raf/MEK/ERK pathways in B-cell lymphomas.

Lymphoma TypemTORC1 activationPI3K/Akt activationMEK/ERK dysregulationRef/s

Hodgkin Lymphoma (HL)Cell lines, tissue samplesCell lines, tissue samples[22]
Tissue samples[23, 24]
Tissue samplesTissue samplesTissue samples[25]
Cell lines, tissue samples[26]

Mantle Cell Lymphoma (MCL)Cell lines, tissue samplesCell lines, tissue samples[27, 28]
Cell linesCell lines, tissue samples[28]
Cell lines, tissue samples[29]
Tissue samples[30]
Cell lines, Lymphoma cells from a MCL patientCell lines, Lymphoma cells from a MCL patientCell lines, Lymphoma cells from a MCL patient[31]

Diffuse Large B-Cell Lymphoma (DLBCL)Tissue samplesTissue samples[32]
Cell lines, tissue samplesCell lines[33]
Tissue samples[34, 35]
Cell lines, tissue samples[36, 37]
Cell linesCell lines [38, 39]

Follicular Lymphoma (FL)Cell lines, tissue samples[40]
Cell linesCell lines[41]
Cell linesCell lines[42]
Cell lines[43, 44]
Cell linesCell lines [45]

Burkitt LymphomaCell lines[24]
Cell linesCell lines[32, 46]

Primary Effusion Lymphoma (PEL)Cell lines, animal model (mice)Cell lines, animal model (mice)[47, 48]
Cell linesCell lines[24]

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.